Lixisenatide | CAS 320367-13-3 | GLP-1 Receptor Agonist (Research Use Only) | Knowlux

Product Description

Lixisenatide, CAS 320367-13-3, is a synthetic GLP-1 receptor agonist supplied by Knowlux for laboratory research use. It is a 44-amino-acid peptide based on the exendin-4 backbone with C-terminal modification, conferring resistance to DPP-IV degradation and supporting once-daily subcutaneous administration. The molecular formula is C215H347N61O65S and the molecular weight is 4858.49 g/mol. Each lot is released with a lot-specific COA, MSDS and full analytical traceability.

Product Parameters

Product Details

1. Overview

Lixisenatide is a short-acting GLP-1 receptor agonist developed by Sanofi and approved as Lyxumia in the EU and Adlyxin in the US for glycaemic control in type 2 diabetes. It is structurally derived from exendin-4, the same peptide backbone as exenatide, but carries a C-terminal hexa-lysine extension that alters its receptor binding kinetics and duration of action. Knowlux supplies lixisenatide as a research-grade peptide for laboratory and analytical use; this supply is not intended for human administration and does not constitute a finished drug product.

2. Mechanism of Action

Lixisenatide binds and activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon release during hyperglycaemia, and slowing gastric emptying. Its DPP-IV resistance, conferred by the exendin-4 backbone, gives it a circulating half-life substantially longer than native GLP-1. The C-terminal lysine extension is associated with a shorter duration of action relative to long-acting GLP-1 analogues, supporting once-daily rather than once-weekly dosing.

3. Quality Control

Full COA, MSDS, and lot-specific chromatograms are issued with each shipment. Custom specifications and third-party inspection can be arranged.

4. Applications

• Reference standard and impurity studies for GLP-1 receptor agonist analytical methods

• GLP-1R binding and functional assay development

• Formulation development for short-acting injectable peptides

• Metabolic disease model research, including glucose homeostasis and gastric emptying studies

• LC-MS, immunoassay and bioassay calibrators

5. Packaging, Storage & Shipping

Lyophilized powder: amber glass vial under nitrogen headspace, sealed with butyl stopper and aluminium crimp. Secondary packing: tamper-evident, light-protected carton with desiccant. Cold-chain shipping with validated gel packs and temperature logger; dry ice for -20 C shipments. COA, MSDS, packing list and certificate of origin issued with each shipment.

6. Documentation Support

Per lot: COA, MSDS, certificate of origin, residual solvent statement, counter-ion specification. Regulatory packages (specification summaries, audit support) available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Lixisenatide is approved as a prescription medicine (Lyxumia, Adlyxin) in many jurisdictions for type 2 diabetes; that regulatory status is specific to the approved pharmaceutical products and does not extend to this research-grade supply as sold by Knowlux. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.